We compared the effectiveness of teclistamab versus real-world physician's choice of therapy (RWPC) in triple-class exposed relapsed/refractory multiple myeloma. MajesTEC-1 eligibility criteria were applied to the RWPC cohort. Baseline covariate imbalances were adjusted using inverse probability of treatment weighting. Overall survival, progression-free survival and time to next treatment were compared. After inverse probability of treatment weighting, baseline characteristics were similar between cohorts (teclistamab, n = 165; RWPC, n = 364 [766 observations]). Teclistamab treated patients had numerically better overall survival (hazard ratio [HR]: 0.82 [95% CI: 0.59-1.14]; p = 0.233) and significantly greater progression-free survival (HR: 0.43 [0.33-0.56]; p < 0.0001) and time to next treatment (HR: 0.36 [0.27-0.49]; p < 0.0001) versus the RWPC cohort. Teclistamab offered clinical benefit over RWPC in triple-class exposed relapsed/refractory multiple myeloma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402759 | PMC |
| http://dx.doi.org/10.57264/cer-2022-0186 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety outcomes of teclistamab accelerated dose escalation.
J Oncol Pharm Pract
August 2024
Department of Pharmacy, University of California Davis Medical Center, Sacramento, CA, USA.
Introduction: Teclistamab, a bispecific T-cell engaging antibody targeting B-cell maturation antigen (BCMA), is indicated for the treatment of relapsed or refractory multiple myeloma after at least four lines of therapy. It has boxed warnings for life threatening cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). To mitigate these risks, teclistamab is initiated using step-up doses.
View Article and Find Full Text PDFA matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma.
Leuk Lymphoma
May 2024
Pfizer Inc., New York, NY, USA.
Article Synopsis
- For patients with triple-class exposed/refractory multiple myeloma (TCE/RMM), B-cell maturation antigen and CD3-directed bispecific antibodies like teclistamab and elranatamab are emerging as new treatment options due to limited existing therapies.
- Teclistamab received conditional approval in Europe and accelerated FDA approval based on the MajesTEC-1 trial, while elranatamab was approved by the FDA following the MagnetisMM-3 trial.
- An indirect comparison showed that elranatamab outperformed teclistamab in terms of objective response rate and progression-free survival, suggesting it may be a more effective treatment for TCE/RMM patients.
Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.
Adv Ther
February 2024
University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
Introduction: Teclistamab is the first approved B cell maturation antigen × CD3 bispecific antibody with precision dosing for the treatment of triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM). We compared the effectiveness of teclistamab in MajesTEC-1 versus real-world physician's choice of therapy (RWPC) in patients from the prospective, non-interventional LocoMMotion and MoMMent studies.
Methods: Patients treated with teclistamab from MajesTEC-1 (N = 165) were compared with an external control arm from LocoMMotion (N = 248) or LocoMMotion + MoMMent pooled (N = 302).
Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma.
J Comp Eff Res
June 2023
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
We compared the effectiveness of teclistamab versus real-world physician's choice of therapy (RWPC) in triple-class exposed relapsed/refractory multiple myeloma. MajesTEC-1 eligibility criteria were applied to the RWPC cohort. Baseline covariate imbalances were adjusted using inverse probability of treatment weighting.
View Article and Find Full Text PDFComparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma.
Clin Lymphoma Myeloma Leuk
May 2023
University Hospital Hôtel-Dieu, Nantes, France.
Background: The efficacy and safety of teclistamab in patients with RRMM who received ≥3 prior lines of therapy and were triple-class exposed (TCE) are being evaluated in the single-arm, multicohort, phase I/II MajesTEC-1 trial (NCT04557098). We evaluated the comparative effectiveness of teclistamab versus physician's choice (PC) of therapy in TCE RRMM patients.
Methods: Individual patient-level data from MajesTEC-1 patients who received teclistamab (1.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!